Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy.
Lamure S, Van Laethem F, De Verbizier D, Lozano C, Gehlkopf E, Tudesq JJ, Serrand C, Benzaoui M, Kanouni T, Quintard A, De Vos J, Tchernonog E, Platon L, Ayrignac X, Ceballos P, Sirvent A, François M, Guedon H, Quittet P, Mongellaz C, Conte A, Herbaux C, Bret C, Taylor N, Dardalhon V, Cartron G.
Lamure S, et al. Among authors: van laethem f.
Cancers (Basel). 2021 Aug 25;13(17):4279. doi: 10.3390/cancers13174279.
Cancers (Basel). 2021.
PMID: 34503088
Free PMC article.